Glucose Health Research and Development Expenses 2014-2019 | GLUC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Glucose Health research and development expenses from 2014 to 2019. Research and development expenses can be defined as an expense arising from studies and product development processes.

Glucose Health Research and Development Expenses 2014-2019 | GLUC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Glucose Health research and development expenses from 2014 to 2019. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$227.2B
Boston Scientific (BSX)	$140.7B
Stryker (SYK)	$132.3B
EssilorLuxottica (ESLOY)	$128.4B
Medtronic (MDT)	$105.9B
Lonza Group Ag (LZAGY)	$47.4B
Haleon (HLN)	$46.2B
ResMed (RMD)	$31.3B
Agilent Technologies (A)	$29.2B
GE HealthCare Technologies (GEHC)	$28.6B
Terumo (TRUMY)	$28.2B
Koninklijke Philips (PHG)	$22.2B
Zimmer Biomet Holdings (ZBH)	$19.4B
Insulet (PODD)	$17.3B
Baxter (BAX)	$14.8B
Smith & Nephew SNATS (SNN)	$11.4B
Sunny Optical Technology (SNPTF)	$7.6B
Lantheus Holdings (LNTH)	$6.9B
Bio-Rad Laboratories (BIO)	$6.7B
Demant (WILYY)	$6.6B
Prestige Consumer Healthcare (PBH)	$4B
Shandong Weigao Medical Polymer (SHWGF)	$3.5B
Perrigo (PRGO)	$3.5B
ICU Medical (ICUI)	$3.4B
Haemonetics (HAE)	$2.9B
Envista Holdings (NVST)	$2.6B
GN Store Nord (GNNDY)	$2.2B
LeMaitre Vascular (LMAT)	$1.9B
QuidelOrtho (QDEL)	$1.7B
AtriCure (ATRC)	$1.6B